INSIDE THIS ISSUE

- Benefit Drug List
- Patient Education - Breast Cancer
  Chemotherapy Information, Natural Health Products and Breast Cancer
- Protocol Update – BRAJFEC, CNCCNU, CNTEMOZ, LYGDP
- Cancer Management Manual – Colorectal Cancer Management: Palliative Treatment
- Pre-Printed Order Update – GIFUFA, GIFFAD, UGIFOLFOX, LUDOC, BRAVDOC, CNTEMOZ, LUPG, GIERNALT, LYCHOP, GAUVPG, LYRITUX, CNCCV, BRAVTR, LUPAVESL, LUPAVESE, BRAJCEF-G, GIRAI, GIFUR2, GIRLAIFF, GUBCV, HNDE, BRAVTRNAV
- Cancer Drug Manual
- Provincial Systemic Therapy Program Policies
- Communities Oncology Network – Chemotherapy Nurse Certification, Nursing Section on BCCA Website
- Library/Cancer Information Centre – Unconventional Drug Therapies Manual

FAX request form and IN TOUCH phone list are provided if additional information is needed.

HIGHLIGHT OF PROTOCOL CHANGES

Breast A new protocol, BRAJFEC (alternatively known as FEC100), has been implemented. This protocol is designed for patients who have poorly tolerated the preferred treatment, BRAJCEF. BRAJFEC involves the use of the same drugs as BRAJCEF but with different dosing regimens.

BENEFIT DRUG LIST

The current Benefit Drug List, Class II forms and Undesignated Indication application forms are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Frequently Used Forms.

INDEX OF NEW AND REVISED PROTOCOLS

INDEX to BC Cancer Agency Protocol Summaries revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version). Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter U.

- BRAJFEC new: Adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide
- CNCCNU revised (title and eligibility revised): Treatment of recurrent malignant brain tumors
- CNTEMOZ revised (title revised): Therapy for malignant brain tumours using temozolomide
- LYGDP revised (CBC test clarified): Treatment of lymphoma with gemcitabine, dexamethasone and cisplatin

Protocols are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols.

CANCER MANAGEMENT MANUAL

Colorectal Cancer Palliative management of colon cancer (section 5.5) of rectal cancer (section 6.5) have been revised to reflect the recent introduction of new chemotherapy regimens for this patient population.

The Cancer Management Manual is available are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Cancer Management Guidelines.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BC Cancer Agency protocol summaries. The BC Cancer Agency Vancouver Centre has prepared chemotherapy pre-printed orders, which can be used as a guide for reference. An index to the orders can be obtained by Fax-back.
- **BRAJCEF-G** revised (premedications instructions): Adjuvant therapy for breast cancer using cyclophosphamide, epirubicin and fluorouracil

- **BRAVDOC** revised (docetaxel dilution volume and administration rate): Palliative therapy for metastatic breast cancer using docetaxel (Taxotere®)

- **BRAVTR** revised (replacing UBRAVTR): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®)

- **BRAVTRNAV** Revised (bookings for every 3 weeks): palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) and vinorelbine

- **CNCCV** revised (different strengths of capsules added): Adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuro-ectodermal tumour (PNET)

- **CNTEMOZ** revised (indications): First line therapy for malignant brain tumours using temozolomide

- **GIFUFA** revised (dosing options for Fluouracil): Palliative therapy of advanced colorectal cancer using leucovorin and fluorouracil

- **GIFFAD** revised (dosing options for Fluouracil): Adjuvant therapy for stage III and high risk stage II colon cancer using leucovorin and fluorouracil

- **UGIFOLFOX** revised (appointment times, leucovorin dose): Palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, 5-fluorouracil and folinic acid (leucovorin)

- **GIFUR2** revised (premedications instructions): Combined modality adjuvant therapy for high risk rectal carcinoma using fluorouracil, leucovorin, and radiation therapy

- **GIGAI** revised (premedications instructions): Combined modality adjuvant therapy for completely resected gastric adenocarcinoma using fluorouracil + folinic acid (leucovorin) + radiation therapy

- **GIIRINALT** revised (replaces UGIIRINALT as now Class II Status): Second-line treatment for fluorouracil-refractory metastatic colorectal cancer using irinotecan in high risk patients

- **GIRAI** revised (premedications instructions): adjuvant therapy for rectal carcinoma using fluorouracil + leucovorin + XRT

- **GIRLAIFF** revised (premedications instructions): Preoperative concurrent chemotherapy and radiotherapy and postoperative chemotherapy for locally-advanced (borderline resectable or unresectable) rectal adenocarcinoma

- **GUAVPG** revised (under the section "Indication for use of Gemcitabine (and Cisplatin) Class II Drug", now reads "For advanced urothelial carcinoma"): Palliative therapy for urothelial carcinoma using cisplatin and gemcitabine

- **GUBCV** revised (premedications instructions): Therapy for transitional cell cancers using carboplatin-vinblastine

- **HNDE** new: Recurrent and metastatic nasopharyngeal cancer using cisplatin and etoposide

- **LUDOC** revised (infusion rate): Second-line treatment for advanced non-small cell lung cancer (NSCLC) with docetaxel (Taxotere®)

- **LUPAVESE** revised (antiemetic instructions and Etoposide reaction instructions): Treatment for extensive stage small cell lung cancer (SCLC) with cisplatin, doxorubicin, vincristine and etoposide (PAVE)

- **LUPAVESL** revised (antiemetic instructions and etoposide reaction instructions): Concurrent EP and thoracic radiotherapy for limited stage SCLC using cisplatin, doxorubicin, vincristine and etoposide

- **LUPG** new: Treatment of malignant mesothelioma with cisplatin and gemcitabine

- **LYCHOP** revised (cyclophosphamide preparation instructions): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP)

- **LYRITUX** revised (under the treatment section, added "For All Cycles: Treatment not to start after 1300 unless physician is in the building during entire time of dosage increases and until patient is at stable rate."): Treatment of lymphoma with single agent rituximab
**PATIENT EDUCATION**

**Breast Cancer Chemotherapy Information**
Information handouts on a number of treatment protocols that have been specifically developed for patients are now available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Information for the Patient.

**Natural Health Products and Breast Cancer**
A patient information handout has been developed by the BCCA Breast Tumour Group. This is now available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Cancer Management Guidelines, Breast Tumour, Patient Resources.

**FOCUS ON OXALIPLATIN-BASED TREATMENT FOR COLORECTAL CANCER**

**UGIFOLFOX** is the BCCA protocol indicated for palliative combination chemotherapy in metastatic colorectal cancer using oxaliplatin, 5-fluorouracil and folinic acid (leucovorin). Oxaliplatin reimbursement requires undesignated approval from BCCA. The product is made by Sanofi Synthelabo, and is available only through Health Canada’s Special Access Program. It may take up to two weeks for the drug to arrive in B.C. after approval from Health Canada has been obtained.

Oxaliplatin is an alkylating agent, belonging to a new class of platinum agents. It is not generally cross-resistant to either cisplatin or carboplatin, and has been shown to be synergistic with fluorouracil and the active metabolite of irinotecan, SN-38. The NCIC CO13 trial is currently looking at a comparison of a combination of treatments involving oxaliplatin, irinotecan and fluorouracil.

**Dosing Regimen**
The UGIFOLFOX protocol uses Oxaliplatin at a dose of 100 mg/m². Although doses of 85 mg/m² have been used, the highest response rate has been observed with 100 mg/m². Fluorouracil is dosed at 2400 mg/m², with an escalation to 3000 mg/m² at cycle 3, if the patient has experienced less than or equal to Grade 2 toxicity. Effective December 1, 2002, the dose of folinic acid was increased from 200 mg/m² to 400 mg/m². This was done to standardize the BCCA treatment to the European protocol, FOLFOX6, now the standard FOLFOX regimen in Europe. Note that folinic acid is available in Canada as a racemic mixture of D- and L-isomers (Leucovorin). The L-isomer is deemed to be responsible for the biological activity and may have a more favourable profile of physical compatibility with other drugs. L-isomer only folinic acid is available in France (Elvorine®) and the UK (Isovorin®).

Research in Europe is looking at increasing the dose of oxaliplatin even further. The FOLFOX7 protocol is being used in a phase II study of high dose intensity oxaliplatin (130 mg/m²) combined with a lower dose of Fluorouracil (2400 mg/m² with no dose escalation). Initial results indicate this regimen is highly active, with good tolerability in pre-treated patients resistant to Folinic Acid and Fluorouracil, in metastatic colorectal cancer.

**Administration of Oxaliplatin**
Of particular interest in this protocol is the question of concurrent administration of oxaliplatin and folinic acid. The administration options at this time are to administer the two drugs sequentially, to administer them concurrently through a peripheral line, or to administer them concurrently through a central venous line (e.g., PICC). Currently, the protocol indicates that oxaliplatin and folinic acid may be infused over the same 2-hour period. It is key that the two drugs mix minimally in the IV tubing. The most cost-effective way of doing this is to connect a second “primary” line to the lowest side port of the true primary IV. You can then infuse one drug through each of these primary lines as a secondary medication. A Y-connector, placed directly before the IV site, can be used to achieve the same goal but involves extra expense. These drugs should not be combined in the same infusion bag. Oxaliplatin is not compatible with normal saline or other alkaline solutions; therefore folinic acid is diluted using D5W, and lines should not be flushed with saline.

**Toxicities**
Peripheral sensory neuropathy is a dose-limiting side effect of oxaliplatin, with symptoms including sensory ataxia, and dysesthesia of the limbs, mouth, throat and larynx. This side effect may be
worsened on exposure to cold, and patients are counseled to avoid cold drinks and exposure to cold air, especially on the day of oxaliplatin treatment. Dose modifications for neurologic toxicity are outlined in the protocol.

Other dose-limiting side effects for this protocol include hematologic toxicities (myelosuppression), and non-hematologic, non-neurologic toxicities (diarrhea and mucositis). Oxaliplatin as a single agent causes only a 4% occurrence in mucositis, but this increases to a 42% occurrence when combined with 5FU and folinic acid. An additive effect is also seen in diarrhea, when as a single agent oxaliplatin causes a 41% occurrence, which is increased to 58% when combined with 5FU and folinic acid. Dose modifications for these side effects are outlined in the protocol.

References:
4. Personal communication. S Walisser, BSc(Pharm), Professional Practice Leader, BCCA, 31 October 2002.
Wendy Ennion (VC)

Community Hospital Nurses
Liz Chamberlin (Williams Lake)
Linda Hicks (Williams Lake)
Darlene Peterson (Abbotsford)

Chemotherapy Courses 2003
4 courses have been scheduled for 2003. The 2 classroom days for each of these courses are:
February 16, 17
June 16, 17
September 22, 23
November 17, 18

Please call Judy Oliver at (604) 8776098, L. 2639 or Email joliver@bccancer.bc.ca for further information about these courses.

Nursing Section on BCCA Website
At the Partners in Oncology Conference in November, we announced plans to create a nursing section within the BCCA website. Plans are moving along and starting January 13, 2003, you will find the website up and running. We have identified 3 main areas for our website:
- Resources for practice
- Communication
- Education

Our first priority is to make our Nursing References available on-line and this might take a little time. In the meantime, look for the listing of the oncology nursing educational events that we will be offering in the coming year!

Submitted by
Judy Oliver, RN, BScN, MEd
Education Resource Nurse
BCCA

**PROVINCIAL SYSTEMIC THERAPY PROGRAM POLICIES**

BC Cancer Agency Systemic Therapy Policies are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Policies and Procedures.

**LIBRARY/CANCER INFORMATION CENTRE**

**Unconventional Cancer Therapies Manual**
is available on the BC Cancer Agency website www.bccancer.bc.ca under Patient/Public Info, Unconventional Therapies. The manual consists of 46 short monographs on the more commonly used unconventional cancer therapies (e.g., Essiac, vitamins, teas, shark cartilage) and includes tips for the patient and family on how unconventional therapies can be evaluated. For each therapy the manual provides proponent/advocate claims, as well as evidence-based evaluation/critique quotations from the literature.

**Editorial Review Board**
Mário de Lemos, PharmD (Editor)
Cicely Bryce, MD
Sandra Broughton, MSc
Karen Janes, MSN
Beth Morrison, MLS
Jaya Venkatesh, MHA
Susan Walisser, BSc (Pharm)
Gigi Concon (Secretary)
<table>
<thead>
<tr>
<th>Department</th>
<th>Phone</th>
<th>Toll-Free Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>BC Cancer Agency</td>
<td>(604)-877-6000</td>
<td>Toll-Free 1-(800)-663-3333</td>
<td><a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Communities Oncology Network</td>
<td>Ext 2744</td>
<td></td>
<td><a href="mailto:jvenkate@bccancer.bc.ca">jvenkate@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Education Resource Nurse</td>
<td>Ext 2638</td>
<td></td>
<td><a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Nursing Professional Practice</td>
<td>Ext 2623</td>
<td></td>
<td><a href="mailto:ilundie@bccancer.bc.ca">ilundie@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Pharmacy Professional Practice</td>
<td>Ext 2247</td>
<td></td>
<td><a href="mailto:gconcon@bccancer.bc.ca">gconcon@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Provincial Systemic Therapy Program</td>
<td>Ext 2247</td>
<td></td>
<td><a href="mailto:francish@bccancer.bc.ca">francish@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Communities Oncology Network Pharmacist</td>
<td>Ext 6277</td>
<td></td>
<td><a href="mailto:robrien@bccancer.bc.ca">robrien@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Drug Information</td>
<td>Ext 6275</td>
<td></td>
<td><a href="mailto:bethm@bccancer.bc.ca">bethm@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Library / Cancer Information</td>
<td>Ext 2690</td>
<td></td>
<td><a href="mailto:mdelemos@bccancer.bc.ca">mdelemos@bccancer.bc.ca</a></td>
</tr>
<tr>
<td>Update Editor</td>
<td>Ext 2288</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centre for the Southern Interior (CCSI)</td>
<td>(250) 712-3900</td>
<td>Toll-Free 1-(888)-563-7773</td>
<td></td>
</tr>
<tr>
<td>Fraser Valley Centre (FVCC)</td>
<td>(604)-930-2098</td>
<td>Toll-Free 1-(800)-523-2885</td>
<td></td>
</tr>
<tr>
<td>Vancouver Centre (VCC)</td>
<td>(604)-877-6000</td>
<td>Toll-Free 1-(800)-663-3333</td>
<td></td>
</tr>
<tr>
<td>Vancouver Island Centre (VICC)</td>
<td>(250) 519-5500</td>
<td>Toll-Free 1-(800)-670-3322</td>
<td></td>
</tr>
</tbody>
</table>
For easy access, double-click your systemic chemo icon.
We appreciate your comments. Write us at bulletin@bccancer.bc.ca
## BC CANCER AGENCY SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

**TO SUBSCRIBE:** FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

**FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247**

**OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247**

**PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES**

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

- E-mail (Word 6.0)
- Fax

**UPDATES** Please ☑ Fax-Back information below:

<table>
<thead>
<tr>
<th>Item</th>
<th>Code</th>
<th>Pre-printed Orders</th>
<th>Protocol Summaries: (also available on our website <a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All items</td>
<td></td>
<td>All items</td>
<td>All items</td>
</tr>
<tr>
<td>Cancer Drug Manual Monographs (also available on our website <a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>)</td>
<td></td>
<td></td>
<td>All items</td>
</tr>
<tr>
<td>Patient Education Handout (also available on our website <a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>)</td>
<td></td>
<td></td>
<td>All items</td>
</tr>
<tr>
<td>Pre-printed Orders:</td>
<td></td>
<td></td>
<td>All items</td>
</tr>
<tr>
<td>BRAJCEF-G</td>
<td></td>
<td>BRAJCEF-G</td>
<td>BRAJCEF-G</td>
</tr>
<tr>
<td>CNTEMOZ</td>
<td></td>
<td>CNTEMOZ</td>
<td>CNTEMOZ</td>
</tr>
<tr>
<td>GIGAI</td>
<td></td>
<td>GIGAI</td>
<td>GIGAI</td>
</tr>
<tr>
<td>GUBCV</td>
<td></td>
<td>GUBCV</td>
<td>GUBCV</td>
</tr>
<tr>
<td>LUPG</td>
<td></td>
<td>LUPG</td>
<td>LUPG</td>
</tr>
<tr>
<td>BRAVDOC</td>
<td></td>
<td>BRAVDOC</td>
<td>BRAVDOC</td>
</tr>
<tr>
<td>GIFUFA</td>
<td></td>
<td>GIFUFA</td>
<td>GIFUFA</td>
</tr>
<tr>
<td>GIIRINALT</td>
<td></td>
<td>GIIRINALT</td>
<td>GIIRINALT</td>
</tr>
<tr>
<td>HNDE</td>
<td></td>
<td>HNDE</td>
<td>HNDE</td>
</tr>
<tr>
<td>LUPG</td>
<td></td>
<td>LUPG</td>
<td>LUPG</td>
</tr>
<tr>
<td>BRAVTR</td>
<td></td>
<td>BRAVTR</td>
<td>BRAVTR</td>
</tr>
<tr>
<td>GIFFAD</td>
<td></td>
<td>GIFFAD</td>
<td>GIFFAD</td>
</tr>
<tr>
<td>GIRAI</td>
<td></td>
<td>GIRAI</td>
<td>GIRAI</td>
</tr>
<tr>
<td>LUDOCH</td>
<td></td>
<td>LUDOCH</td>
<td>LUDOCH</td>
</tr>
<tr>
<td>LYRITUX</td>
<td></td>
<td>LYRITUX</td>
<td>LYRITUX</td>
</tr>
<tr>
<td>BRAVTRNAV</td>
<td></td>
<td>BRAVTRNAV</td>
<td>BRAVTRNAV</td>
</tr>
<tr>
<td>UGIFOLFOX</td>
<td></td>
<td>UGIFOLFOX</td>
<td>UGIFOLFOX</td>
</tr>
<tr>
<td>GIRLAIFF</td>
<td></td>
<td>GIRLAIFF</td>
<td>GIRLAIFF</td>
</tr>
<tr>
<td>LUPAVESE</td>
<td></td>
<td>LUPAVESE</td>
<td>LUPAVESE</td>
</tr>
<tr>
<td>CNCCV</td>
<td></td>
<td>CNCCV</td>
<td>CNCCV</td>
</tr>
<tr>
<td>GIFUR2</td>
<td></td>
<td>GIFUR2</td>
<td>GIFUR2</td>
</tr>
<tr>
<td>GUAVPG</td>
<td></td>
<td>GUAVPG</td>
<td>GUAVPG</td>
</tr>
<tr>
<td>LUPAVESL</td>
<td></td>
<td>LUPAVESL</td>
<td>LUPAVESL</td>
</tr>
<tr>
<td>Protocol Summaries: (also available on our website <a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>)</td>
<td></td>
<td></td>
<td>Protocol Summaries: (also available on our website <a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>)</td>
</tr>
<tr>
<td>BRAJFEC</td>
<td></td>
<td>BRAJFEC</td>
<td>BRAJFEC</td>
</tr>
<tr>
<td>CNTEMOZ</td>
<td></td>
<td>CNTEMOZ</td>
<td>CNTEMOZ</td>
</tr>
<tr>
<td>LYGDP</td>
<td></td>
<td>LYGDP</td>
<td>LYGDP</td>
</tr>
</tbody>
</table>

**Index: Protocol Summaries (current month)**

**Provincial Systemic Therapy Program Policies**

**Reimbursement (also available on our website www.bccancer.bc.ca)**

- Class 2 Form (01 Dec 2002)
- Filgrastim Usage Form (October 2002)
- Undesignated Indication Form (Nov 2002)

**Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca)**

- Jan-Dec 2000
- Jan-Dec 2001
- Jan-Jun 2002